BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Dr Reddy’s Q2 Results FY25–26: Revenue, Profit & Highlights

Dr Reddy’s Q2 Results FY25–26: Revenue, Profit & Highlights

Synopsis:


Dr Reddy’s Laboratories posted consolidated revenue of ₹8,805 Crore in Q2 FY25–26, up 9.8% YoY and 3% QoQ. Net profit rose to ₹1,426 Crore, supported by broad-based growth across branded generics and the Nicotine Replacement Therapy portfolio.


Source: Dr Reddy’s Laboratories Ltd Unaudited Consolidated Financial Results (BSE filing) | Published on Oct 24 2025

Dr Reddy’s Laboratories Ltd announced its unaudited results for the quarter ended September 30 2025. The company delivered growth in revenue and profit despite pricing pressure in the US generic segment.

Dr Reddy’s – Q2 FY25–26 Consolidated Results

Particulars

Q2 FY26 (₹ Cr)

Q1 FY26 (₹ Cr)

Q2 FY25 (₹ Cr)

Revenue from Operations

8,805

8,545

8,016

EBITDA

2,351

2,282

2,278

Profit Before Tax (PBT)

1,835

1,904

1,916

Profit After Tax (PAT)

1,426

1,409

1,341

Earnings Per Share (Basic)

₹17.26

₹17.04

₹15.07

Dr Reddy’s Q2 Results FY25–26 Date & Announcement

The Board of Directors approved the unaudited results on October 24, 2025, after a review by the Audit Committee. The meeting was held from 2:00 PM to 3:57 PM IST. No dividend was declared for the quarter.

DR. REDDY S LABORATORIES

Trade

1275.2-2.40 (-0.18 %)

Updated - 05 December 2025
1282.80day high
DAY HIGH
1271.60day low
DAY LOW
1036082
VOLUME (BSE)

Dr Reddy’s Q2 Results FY25–26 – Key Financial Highlights

Particulars (₹ Cr)

Q2 FY26

Q1 FY26

Q2 FY25

Revenue from Operations

8,805

8,545

8,016

EBITDA

2,351

2,282

2,278

Profit Before Tax (PBT)

1,835

1,904

1,916

Net Profit (PAT)

1,426

1,409

1,341

Earnings Per Share (Basic)

₹17.26

₹17.04

₹15.07

YoY decline in margins was mainly due to lower US generic prices and one-off VAT provision costs.

Dr Reddy’s Q2 FY25–26 vs Q2 FY24–25 – Comparison

Particulars

Q2 FY26 (₹ Cr)

Q2 FY25 (₹ Cr)

Revenue from Operations

8,805

8,016

EBITDA

2,351

2,278

Profit After Tax

1,426

1,341

EPS (₹)

17.26

15.07

Dr Reddy’s Q2 Business Segment Performance

Segment

Q2 FY26 Revenue (₹ Cr)

Q2 FY25 Revenue (₹ Cr)

Global Generics (incl. Biologics)

7,849

7,157

Pharmaceutical Services & Active Ingredients (PSAI)

1,158

1,103

Others

1.2

8.9

Regional Break-Up (Within Global Generics)

  • North America: ₹3,240 Cr — price erosion in key products like Lenalidomide.

  • Europe: ₹1,376 Cr — boost from NRT portfolio and new launches.

  • India: ₹1,578 Cr — driven by new brands and higher volumes.

  • Emerging Markets: ₹1,654 Cr — sustained momentum in Russia and CIS regions.

Market Reaction After Dr Reddy’s Q2 Results FY25–26

The results were announced on 24 October 2025, after market hours. On the next trading session (27 October 2025), Dr Reddy’s stock opened marginally higher at around ₹1,282.70 on the NSE. 

(Price data based on NSE closing figures as of Oct 27 2025.)

Conclusion – What Dr Reddy’s Q2 Results Mean for Investors

Dr Reddy’s reported its consolidated financial results for the quarter, with growth across all major metrics compared with the same period last year. The company recorded higher income from operations and an improvement in profit before and after tax. The financial performance captured the outcome of business activity across its product categories and operations during the quarter. 

For more quarterly result updates, visit Bajaj Broking’s Quarterly Results Calendar.

Frequently Asked Questions

No result found

search icon

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.8 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,600+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|